Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,510.00
Bid: 12,524.00
Ask: 12,526.00
Change: 118.00 (0.95%)
Spread: 2.00 (0.016%)
Open: 12,468.00
High: 12,556.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

A quarter of symptomatic kids hit by long COVID; mRNA shots provide best protection in breast milk

Mon, 14th Mar 2022 18:42

March 14 (Reuters) - The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review.

One in four kids with COVID develop lingering problems

One in four children with COVID-19 symptoms develop "long COVID," according to data pooled from 21 earlier studies conducted in Europe, Asia, Australia and South America.

Among the 80,071 children with COVID-19 in the studies, 25% developed symptoms that lasted at least 4-to-12 weeks or new persistent symptoms that appeared within 12 weeks, researchers reported on Sunday on medRxiv https://www.medrxiv.org/content/10.1101/2022.03.10.22272237v1 ahead of peer review. The most frequent problems were neuropsychiatric (mood symptoms, fatigue, sleep disorders, headaches, cognitive alterations, dizziness, balance problems), cardiorespiratory (breathing difficulty, congestion, exercise intolerance, chest pain and tightness, cough, irregular heart rhythm), skin-related (excessive sweating, itchiness, hair loss) and gastrointestinal (abdominal pain, constipation, diarrhea, vomiting, and nausea). Analyses of data pooled from many different studies with different methodologies cannot yield firm conclusions, the researchers acknowledge. What is clear, however, is that "children and adolescents have also physical and mental health consequences derived from COVID-19," said study coauthor Sonia Villapol of Houston Methodist Research Institute in Texas.

"Identifying the main signs and symptoms of pediatric long COVID can help diagnose, develop better treatments, create multidisciplinary teams for optimal clinical management, and find risk factors for prevention."

Vaccine protection in mother's milk strongest after mRNA shots

Women who wish to pass protective antibodies induced by COVID-19 vaccines to their babies via breast milk should opt for the mRNA shots from Moderna or Pfizer/BioNTech , according to a study reported on Monday in JAMA Pediatrics https://jamanetwork.com/journals/jamapediatrics/fullarticle/2789947.

For the study, 124 lactating women each provided 17 milk samples over a period of 100 days. The women had received either an mRNA vaccine or a vector-based vaccine from Johnson & Johnson or AstraZeneca. Researchers measured two types of antibodies in the milk samples - IgA antibodies and IgG antibodies, both of which are thought to play important roles in protecting breastfed infants. Nearly all - 96% to 97% - of the women who received both doses of an mRNA vaccine had detectable IgA antibodies in their milk, while only 39% had antibodies in their milk after two doses of the AstraZeneca shot and 48% after the one-dose J&J vaccine. All the women who received both doses of the Pfizer/BioNTech, Moderna or AstraZeneca vaccines had IgG antibodies, compared to only 28% of women who received J&J's shot.

"An mRNA-based COVID-19 vaccine is the optimal choice for lactating women when they want to transfer breast milk antibodies to their infants," the researchers concluded.

Omicron is infectious on surfaces longer than original virus

Omicron particles remain infectious on surfaces for longer periods than particles of the original SARS-CoV-2, according to laboratory experiments.

Researchers put droplets of infectious virus from the original coronavirus version and the Omicron BA.1 variant on a variety of surfaces at room temperature. On smooth surfaces (glass, stainless steel and plastic sheet), Omicron was still infectious after seven days, whereas particles of the original SARS-CoV-2 were no longer infectious on stainless steel and plastic sheets by day 4 and on glass by day 7, the researchers reported on Thursday on bioRxiv https://www.biorxiv.org/content/10.1101/2022.03.09.483703v1 ahead of peer review. On tissue paper and printing paper, the original virus was no longer infectious at 30 minutes. Omicron was still infectious at 30 minutes, but no longer after an hour, the researchers said.

For the most part, SARS-CoV-2 is transmitted via respiratory droplets in the air. While infection via contact with contaminated surfaces is less common, the new study "highlights the importance of hand hygiene and cleaning on surfaces that are regularly touched by different persons," said study coauthor Leo Poon of the University of Hong Kong. "For surfaces and settings contaminated by a COVID-19 patient, proper cleaning should be done."

Click for a Reuters graphic https://tmsnrt.rs/3c7R3Bl on vaccines in development.

More News
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more
26 Feb 2024 07:22

AstraZeneca's blood-disorder drug recommended for EU approval

(Sharecast News) - European regulators has given the green light to AstraZeneca's blood-disorder drug Voydeya, the biopharma giant announced on Monday.

Read more
22 Feb 2024 17:36

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

Read more
20 Feb 2024 10:29

AstraZeneca acquires US-based biopharmaceutical company

(Sharecast News) - Drugmaker AstraZeneca revealed late on Monday afternoon that it had successfully completed its acquisition of US-based biopharmaceutical company Icosavax.

Read more
20 Feb 2024 09:40

LONDON BROKER RATINGS: JPMorgan cuts Airtel Africa price target by 28%

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
19 Feb 2024 16:51

LONDON MARKET CLOSE: Europe lacks direction on quiet Monday

(Alliance News) - European markets lacked direction on Monday, after a quiet day as the US markets celebrated George Washington's birthday.

Read more
19 Feb 2024 15:59

London close: Stocks manage gains on globally quiet day

(Sharecast News) - London's financial markets finished in positive territory on Monday, with stocks closing in the green after overcoming minor losses earlier in the session.

Read more
19 Feb 2024 15:39

UPDATE: AstraZeneca completes USD1.1 billion acquisition of Icosavax

(Alliance News) - AstraZeneca PLC on Monday said it has completed the acquisition of Icosavax Inc.

Read more
19 Feb 2024 11:51

LONDON MARKET MIDDAY: Stocks lack direction amid quiet start to week

(Alliance News) - Stock prices in London lacked direction at midday Monday, amid a quiet start to the week.

Read more
19 Feb 2024 08:44

LONDON MARKET OPEN: Stocks drift; Currys surges on takeover interest

(Alliance News) - Stock prices in London were looking for direction early Monday, as investors weighed possible trajectories for US interest rate cuts and a China's economic recovery.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.